Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-α signalling pathways

Gastric cancer

(2016) Eric Van Cutsem et al.   LANCET

The utility of MRI for pre-operative T and N staging of gastric carcinoma: a systematic review and meta-analysis

(2015) Z Huang et al.   BRITISH JOURNAL OF RADIOLOGY

ADAM17 regulates IL-1 signaling by selectively releasing IL-1 receptor type 2 from the cell surface

(2015) Shinichi Uchikawa et al.   CYTOKINE

Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma

(2015) H.B. Liu et al.   GENETICS AND MOLECULAR RESEARCH

Subcellular localization and activation of ADAM proteases in the context of FasL shedding in T lymphocytes

(2015) Henriette Ebsen et al.   MOLECULAR IMMUNOLOGY

Therapeutic potential of digitoflavone on diabetic nephropathy: nuclear factor erythroid 2-related factor 2-dependent anti-oxidant and anti-inflammatory effect

(2015) Yang Yang et al.   Scientific Reports

Chemoprevention of dietary digitoflavone on colitis-associated colon tumorigenesis through inducing Nrf2 signaling pathway and inhibition of inflammation

(2014) Yang Yang et al.   Molecular Cancer

Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis

(2013) V S Warneke et al.   BRITISH JOURNAL OF CANCER

RECK Inhibits Stemness Gene Expression and Tumorigenicity of Gastric Cancer Cells by Suppressing ADAM-Mediated Notch1 Activation

(2013) Kun-Jing Hong et al.   JOURNAL OF CELLULAR PHYSIOLOGY

ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway

(2013) Xiang-jun Wang et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

ADAM17, shedding, TACE as therapeutic targets

(2013) Stefan Rose-John   PHARMACOLOGICAL RESEARCH

ADAM17-Mediated Processing of TNF-α Expressed by Antiviral Effector CD8+ T Cells Is Required for Severe T-Cell-Mediated Lung Injury

(2013) Matthew P. DeBerge et al.   PLoS One

Upregulated Expression of ADAM17 Is a Prognostic Marker for Patients With Gastric Cancer

(2012) Zhang-Xuan Shou et al.   ANNALS OF SURGERY

Nardilysin and ADAM proteases promote gastric cancer cell growth by activating intrinsic cytokine signalling via enhanced ectodomain shedding of TNF-α

(2012) Keitaro Kanda et al.   EMBO Molecular Medicine

A Disintegrin and Metalloproteinase 17 (ADAM17) and Epidermal Growth Factor Receptor (EGFR) Signaling Drive the Epithelial Response toStaphylococcus aureusToxic Shock Syndrome Toxin-1 (TSST-1)

(2012) Laura M. Breshears et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Proteoglycan degradation by the ADAMTS family of proteinases

(2011) Heather Stanton et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Prognostic value of ADAM17 in human gastric cancer

(2011) Tie-cheng Zhang et al.   MEDICAL ONCOLOGY

ADAM17: a molecular switch to control inflammation and tissue regeneration

(2011) Jürgen Scheller et al.   TRENDS IN IMMUNOLOGY

The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17: Novel drug targets with therapeutic potential?

(2010) Paul Saftig et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands

(2009) Motomichi Nakagawa et al.   CANCER SCIENCE

Mitochondrial Reactive Oxygen Species Mediate GPCR–induced TACE/ADAM17-dependent Transforming Growth Factor-α Shedding

(2009) Timothy J. Myers et al.   MOLECULAR BIOLOGY OF THE CELL